- Also known as
- Mod GRF 1-29 · Modified GRF (1-29) · CJC-1295 no DAC · tetrasubstituted GRF(1-29)
- Class
- Growth hormone-releasing hormone (GHRH) analogue
- Form
- Lyophilised powder supplied in 10 mg vials
- Sizes
- 10 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 10 mg: 2 mL
What is CJC-1295 (no DAC)?
CJC-1295 (no DAC) ships as a single vial of lyophilised powder containing CJC-1295 with DAC 0 mg. The two compounds carry separate literatures, and the references gathered on this page are those separate studies. The recorded sequence is 29 amino acids with a C-terminal amide: tetrasubstituted GRF(1-29) (D-Ala2, Gln8, Ala15, Leu27) and no maleimido lysine, which leaves it without an albumin-binding group. The published record runs across rat and human models. Among the 6 references set out below, one is a controlled human trial. It comes as lyophilised powder in 10 mg vials, kept in Canadian stock for laboratory research. This is not a drug and is not offered for any use in a person or an animal.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Teichman SL et al.2006 · J Clin Endocrinol Metab · PMID 16352683 | Human, two randomised, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21-61 (n not stated in the abstract). Tested CJC-1295 WITH DAC, not the no-DAC compound | Four ascending single s.c. doses, then two or three weekly or fortnightly doses; the abstract names 30 and 60 micrograms/kg as the better-tolerated doses | 28 and 49 days | A single injection raised mean GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9-11 days. The half-life was 5.8-8.1 days, a result of the DAC and not expected for the no-DAC compound. |
| Ionescu M et al.2006 · J Clin Endocrinol Metab · PMID 17018654 | Human, healthy men aged 20-40 (n not stated in the abstract). Tested CJC-1295 WITH DAC | 60 or 90 micrograms/kg, single injection | Sampling before and 1 week after injection | GH secretion rose while pulse frequency and size were unchanged. Trough GH rose 7.5-fold, mean GH 46% and IGF-I 45%, with no difference between the two doses. |
| Rafferty B et al.1985 · J Endocrinol · PMID 2866222 | Rat (anaesthetised), pharmacokinetic study of native hGRF(1-29)NH2, the unmodified parent peptide | 10 micrograms i.v.; s.c. dose not stated in the abstract | Single dose | After i.v. injection the peptide cleared with half-lives of 1.9 min (distribution) and 10.4 min (elimination). After s.c. injection the amount reaching the circulation was only 4% of the i.v. amount, which the authors put down to rapid breakdown. |
| Gaudreau P et al.1992 · J Med Chem · PMID 1534126 | Rat anterior pituitary membranes, receptor binding assay of hGRF(1-29)NH2 analogues | Not stated in the abstract | Not applicable (binding assay) | Residues in segment 13-21 mattered more for receptor affinity than those in 24-29. Acylating the N-terminus reduced affinity (26-85% of hGRF(1-29)NH2), and replacing the C-terminal amide with a free acid reduced it to 57%. |
| Cervini LA et al.1998 · J Med Chem · PMID 9513600 | In vitro structure-activity study of hGRF(1-29)-NH2 analogues (growth hormone release) | Not stated in the abstract | Not applicable (in vitro) | Single alanine swaps at positions 8, 9, 15, 22 and 28 gave analogues 2-6 times more potent than hGRF(1-40)-OH. Multiple-substituted analogues released growth hormone 11 to 26 times more effectively than the standard. This is the design family Mod GRF 1-29 belongs to; the no-DAC compound itself was not tested. |
| Jetté L et al.2005 · Endocrinology · PMID 15817669 | Rat (Sprague Dawley) and cultured rat anterior pituitary cells. Tested CJC-1295 WITH DAC, compared against native hGRF(1-29) | Not stated in the abstract (s.c.) | Plasma followed beyond 72 h | CJC-1295 is described as a tetrasubstituted hGRF(1-29) with an added maleimido lysine at the C-terminus. It gave a 4-fold larger growth hormone area under the curve over 2 h than hGRF(1-29) and bound to serum albumin within 15 min. This is the paper that defines the difference between the two molecules. |
What these studies don't show: The controlled data is genuine, yet it belongs to one particular setting. The people enrolled, the measures taken and the length of follow-up each set a limit on what the findings can mean. None of it extends to anything the trial protocol did not cover. An HPLC trace reports what is present, and that is a different matter from whether the compound works.
Every study links to its PubMed record. See all CJC-1295 (no DAC) studies in the research library →
CJC-1295 (no DAC) price in Canada: 10mg vial
Buy CJC-1295 (no DAC) in Canada in a 10mg vial and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 10 mg | $38.00 | $3.80/mg |
Starter kit
Is CJC-1295 (no DAC) available in Canada?
No authorized CJC-1295 (no DAC) product is listed in the Drug Product Database. Canada has run no regulatory assessment of its safety, efficacy or quality. We keep it on the shelf as laboratory research material, not for any use in a person or an animal. How Health Canada treats research peptides →
Side effects reported in studies
When a small study reports no effect, that is not proof of safety. Every statement here is linked to the study that recorded it. None of the cited abstracts gives a tolerability finding for CJC-1295 (no DAC). Read more →
Doses used in studies
CJC-1295 (no DAC) FAQ
What is CJC-1295 (no DAC)?
CJC-1295 (no DAC) belongs to the growth hormone-releasing hormone (GHRH) analogue class. Its published record is drawn from rat and human work. Borealis Peptides provides it as lyophilised powder in 10 mg vials for in-vitro laboratory research. None of it is a medicine, and it is not for human or veterinary use. Every study listed here is shown with its model and the result the authors recorded.
Where can I buy CJC-1295 (no DAC) in Canada?
Borealis Peptides dispatches CJC-1295 (no DAC) from stock held in Canada to research and business addresses across the country. The format is 10 mg vials. HPLC testing covers each batch, and the certificate identifies the batch in your particular vial. We accept orders for laboratory research only.
Is CJC-1295 (no DAC) legal in Canada?
No authorized CJC-1295 (no DAC) product is listed in the Drug Product Database. Canada has run no regulatory assessment of its safety, efficacy or quality. We provide it only as laboratory research material and for no use in a person or an animal. Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, so we treat it as marking what the material is meant for, not clearance to use it.
How much CJC-1295 (no DAC) should I use?
There is nothing to give. This site holds no protocol, no schedule and no reconstitution volume. The quantities in the cited studies belong to those studies and the models they ran in; they appear so that the evidence can be weighed rather than accepted on trust.
What human evidence is there for CJC-1295 (no DAC)?
One of the 6 cited studies is a controlled trial in people, and the remainder are animal or cell work. Each row lists its model, the amount used and the authors' reported outcome, so every study can be weighed on its own terms instead of through a summary.
How long does CJC-1295 (no DAC) keep?
Hold the sealed vial at −20 °C, out of light and moisture. After reconstitution, keep it at 2–8 °C. The dry form is stable at room temperature, so no cold chain is needed in transit; refrigerate on arrival. A lyophilised peptide is degraded by light and temperature cycling rather than by how long it spends shipping.
How is the purity of CJC-1295 (no DAC) confirmed?
HPLC testing is done on every batch before sale, and the certificate points to the batch in your vial rather than to the product as a whole. Holding on to that batch number alongside your records is what lets an observation be reproduced later. Certificates can be supplied on request.
How does CJC-1295 (no DAC) compare with CJC-1295 + Ipamorelin and Ipamorelin?
They are distinct compounds with distinct literatures, and no ranking is given here. CJC-1295 + Ipamorelin and Ipamorelin have 8 cited studies and 8 cited studies on their page against 6 here. The comparison worth making is to read both tables alongside the models each one used.
Why is CJC-1295 (no DAC) named in a Health Canada advisory?
Because it was one of the peptides seized from sellers offering unauthorized injectable products online. That advisory deals with material sold for people to inject without authorization. Borealis Peptides carries research material for in-vitro work alone and sells nothing for injection or for any use in a person, keeping to the side of the line the advisory draws.






